- Home
- NYC vs PLUR Comparison
NYC vs PLUR Comparison
Compare NYC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | PLUR |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 28.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NYC | PLUR |
|---|---|---|
| Price | $11.38 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 6.7K | ★ 9.9K |
| Earning Date | 03-18-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,688,000.00 | $1,326,000.00 |
| Revenue This Year | $8.40 | $97.38 |
| Revenue Next Year | $1.62 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $7.03 | $2.82 |
| 52 Week High | $16.30 | $7.13 |
Technical Indicators
Market Signals| Indicator | NYC | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 71.14 | 54.35 |
| Support Level | $9.93 | $3.00 |
| Resistance Level | $11.99 | $3.50 |
| Average True Range (ATR) | 0.75 | 0.15 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 81.17 | 64.00 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.